Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the pathophysiological characteristics and treatment options for polycystic ovary syndrome, reporting no new clinical results; the authors emphasize combining non-pharmacological measures with pharmacological treatments for optimal patient management.

This review discusses the pathophysiology of polycystic ovary syndrome and its non-pharmacological and pharmacological treatment options, but reports no new clinical results.

This study describes a planned multicenter randomized controlled trial to assess the safety, tolerability, and pharmacokinetics of subdermal gestrinone pellets in patients with deep infiltrative endometriosis-related pelvic pain, but it does not report any findings yet.

Different skin conditions show distinct types of vessel inflammation, a new quality of life index for vulval disease is reliable, a certain intrauterine system might be linked to chronic vaginal yeast infections, and oral minoxidil reduces hair loss in women.

This review discusses non-oral hormonal contraceptives and other exogenous steroid hormones, reporting they are generally safe for temporary use in women without breast cancer, but data are limited.

This review discusses recent advancements in female contraception and covers topics like adapted regimens, non-invasive sterilization, and the promise of new methods, but it reports no new clinical findings.

This letter highlights that levonorgestrel intrauterine devices may lead to fewer systemic side effects, like acne, compared to its oral administration due to lower systemic levels of progestogens.

This study suggests that lower-dose ethinyl estradiol formulations and progestin-only contraceptives may offer safer options for managing PCOS in obese women due to minimal metabolic effects.

This study analyzed adverse event reports from the FDA database and found that drugs such as immunomodulatory agents, monoclonal antibodies, minoxidil, contraceptives, and anti-TNF drugs are frequently associated with hair loss, suggesting guidance for dermatologists in identifying common medications linked to alopecia.

This review discusses the effects and selection criteria of different progestogens in various treatments but reports no direct clinical comparisons of their metabolic effects.

This review discusses the role of contraceptives in dermatology, particularly for acne treatment and managing patients on teratogens, but reports no new clinical results.

This review examines the role of hormones in acne pathogenesis, the use of hormonal therapies for treatment, and the importance of contraceptive counseling during isotretinoin therapy, but reports no new clinical results.

This review discusses the multi-system impacts of polycystic ovary syndrome and explores evaluation and treatment strategies, but it reports no new research findings.

This pharmacovigilance study identified 64 drugs linked to hair loss, revealing specific demographic trends and timing patterns, and emphasized the importance of gender-specific monitoring and label updates to better convey real-world risks.

This study observed that Nigerian women with PCOS have significantly higher levels of myocardial biomarkers (MYO, cTnI, CK-MB), indicating potential chronic, subclinical myocardial injury in this population.

This review discusses how various reproductive factors are linked to increased risks of hypertension and cardiovascular disease, noting associations with impaired fetal growth, male hypogonadism, and effects of contraceptive use, but reports no new results.

This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.

This article discusses the importance of recognizing and distinguishing polycystic ovary syndrome from similar endocrine disorders, and reports no new clinical results.

This article discusses the complexities of androgen and antiandrogen therapies in women, detailing diagnostic measures, the effects on libido, and the potential benefits of new progestins with antiandrogenic properties, but presents no new empirical findings.

This review discusses the diagnostic criteria and treatment options for polycystic ovary syndrome focusing on metabolic subtypes and reports no clinical results.

This source highlights the role of progestin in contraception, noting that while different types have varying progesteronic potential and effects, they share similar contraceptive mechanisms, allowing tailored use based on patient conditions.

This review found that hormones significantly impact women's health and athletic performance, influencing the menstrual cycle, menopause, and exercise responses, while therapies like contraception and hormone replacement require personalized approaches to balance benefits and risks.

This book reviews evidence-based medicine practices in obstetrics and gynecology but reports no new clinical findings.

The estradiol valerate/dienogest oral contraceptive helps with heavy periods, may improve acne and symptoms in PCOS, and doesn't affect sexual function.

This review discusses the prevalence and management of polycystic ovary syndrome in women, particularly noting gaps in understanding its presence in adolescents, and reports no new clinical findings.

In this study, the analysis of PCOS subreddit data revealed that lifestyle changes and supplements were perceived positively for managing PCOS symptoms, while contraceptives were often linked with negative experiences, except when they included anti-androgenic progestins.

This study found that acne prevalence among adults in Greater Porto's primary healthcare centers was 61.5%, with only 25% of those with acne seeking treatment.

This study found that the prevalence of polycystic ovary syndrome was 16.6% with Rotterdam criteria but decreased to 6.3% or 8.5% when using alternative criteria involving antral follicle count or anti-Müllerian hormone.

This review discusses the various evidence-based and potential applications of metformin in treating and preventing symptoms and complications associated with polycystic ovary syndrome but reports no new clinical results.